tiprankstipranks
Trending News
More News >
Enzo Biochem (ENZ)
NYSE:ENZ
Advertisement

Enzo Biochem (ENZ) Price & Analysis

Compare
187 Followers

ENZ Stock Chart & Stats


Enzo Biochem News

ENZ FAQ

What was Enzo Biochem’s price range in the past 12 months?
Enzo Biochem lowest stock price was $0.25 and its highest was $1.27 in the past 12 months.
    What is Enzo Biochem’s market cap?
    Enzo Biochem’s market cap is $16.77M.
      When is Enzo Biochem’s upcoming earnings report date?
      Enzo Biochem’s upcoming earnings report date is Jun 16, 2025 which is 54 days ago.
        How were Enzo Biochem’s earnings last quarter?
        Currently, no data Available
        Is Enzo Biochem overvalued?
        According to Wall Street analysts Enzo Biochem’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Enzo Biochem pay dividends?
          Enzo Biochem does not currently pay dividends.
          What is Enzo Biochem’s EPS estimate?
          Enzo Biochem’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Enzo Biochem have?
          Enzo Biochem has 52,402,805 shares outstanding.
            What happened to Enzo Biochem’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Enzo Biochem?
            Currently, no hedge funds are holding shares in ENZ

            Enzo Biochem Stock Smart Score

            4
            Neutral
            1
            2
            3
            4
            5
            6
            7
            8
            9
            10

            Fundamentals

            Return on Equity
            -12.94%
            Trailing 12-Months
            Asset Growth
            -31.86%
            Trailing 12-Months

            Company Description

            Enzo Biochem

            Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

            Enzo Biochem (ENZ) Earnings & Revenues

            Currently, no data available
            Please return soon. This page is being updated.
            Similar Stocks
            Company
            Price & Change
            Follow
            IGC Pharma
            Tvardi Therapeutics
            Enlivex
            BioAtla
            Neurosense Therapeutics Ltd.

            Ownership Overview

            12.08%4.50%0.03%79.95%
            12.08% Insiders
            0.03% Other Institutional Investors
            79.95% Public Companies and
            Individual Investors
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis